Valuation: ImmuCell Corporation

Market Cap 102M 89.24M 83.1M 76.43M 143M 9.71B 146M 986M 386M 4.82B 382M 374M 16.65B P/E 2024
-19.5x
P/E 2025 -51.3x
Enterprise Value 111M 97.48M 90.77M 83.49M 157M 10.61B 159M 1.08B 422M 5.26B 417M 408M 18.18B EV / Sales 2024
2.16x
EV / Sales 2025 2.35x
Free-Float
67.43%
Yield 2024 *
-
Yield 2025 -
1 day+0.99%
1 week+0.40%
Current month+11.84%
1 month+14.81%
3 months+34.61%
6 months+76.59%
Current year+82.76%
1 week 10.9
Extreme 10.9
11.35
1 month 9.88
Extreme 9.876
12.1
Current year 5.75
Extreme 5.75
12.1
1 year 4.52
Extreme 4.52
12.1
3 years 3.34
Extreme 3.34
12.1
5 years 3.34
Extreme 3.34
12.1
10 years 0
Extreme 0
13.2
Manager TitleAgeSince
Chief Executive Officer 54 01/11/2025
Director of Finance/CFO 47 07/04/2025
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 69 01/12/2013
Director/Board Member 61 31/03/2014
Director/Board Member 66 10/06/2020
Date Insider Type Main position Quantity % Market Cap.
6/18/26 A Buy

Chief Executive Officer

8,000 0.0884%
4/15/26 A Free

Chairman

11,933 0.1319%
4/15/26 A Other

Director

17,899 0.1979%
Change 5-day change 1-year change 3-year change Capi.($)
+0.99%+0.40%+69.53%+112.88% 102M
+1.93%+3.85%+51.05%+166.24% 1,089B
+0.29%+6.43%+60.47%+52.87% 643B
+2.45%+2.77%+39.61%+74.48% 465B
+0.45%+10.98%+42.16%+36.33% 359B
+0.49%+4.47%+38.24%+43.78% 303B
+1.33%+3.05%+17.31%+17.02% 267B
-0.22%+4.96%-3.33%-38.59% 226B
+4.48%+7.33%+30.47%+66.31% 212B
+2.91%+3.10%+18.84%+74.76% 167B
Average +1.57%+4.55%+36.44%+60.61% 373.12B
Weighted average by Cap. +1.59%+5.14%+41.03%+79.94%

Financials

2024 2025
Net sales 26.49M 23.25M 21.65M 19.91M 37.33M 2.53B 37.97M 257M 101M 1.26B 99.46M 97.31M 4.34B 27.64M 24.26M 22.59M 20.78M 38.95M 2.64B 39.62M 268M 105M 1.31B 104M 102M 4.53B
Net income -2.16M -1.89M -1.76M -1.62M -3.04M -206M -3.09M -20.91M -8.18M -102M -8.1M -7.92M -353M -1.04M -913K -850K -782K -1.47M -99.36M -1.49M -10.08M -3.95M -49.28M -3.9M -3.82M -170M
Net Debt 11.34M 9.95M 9.27M 8.52M 15.98M 1.08B 16.25M 110M 43.04M 537M 42.58M 41.66M 1.86B 9.39M 8.24M 7.67M 7.06M 13.23M 897M 13.45M 91.02M 35.62M 445M 35.24M 34.48M 1.54B
Logo ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Employees
73
Date Price Change Volume
28/07/26 $11.24 +0.99% 8,691
27/07/26 $11.13 +0.91% 15,237
24/07/26 $11.03 +0.91% 8,707
23/07/26 $10.93 -1.80% 19,735
22/07/26 $11.13 -0.58% 23,544
  1. Stock Market
  2. Stocks
  3. ICCC Stock